Abstract: A method for removing contaminants from soil site regions in which at least one source electrode is positioned in the soil site and is surrounded by a plurality of sink electrodes so that voltage gradients are established between the source electrode and the sink electrodes. A purging liquid is supplied to the source electrode and is permitted to flow therefrom into the soil site. The voltage gradients cause the purging liquid to move by electroosmosis through the soil site toward the sink electrodes to displace the contaminant material therein and to cause a substantial portion of the contaminant to be moved into the sink electrodes from which the contaminant can be removed.

Abstract: Disclosed are several oral hygiene preparations including plaque disrupting and gingivitis control preparations in the form of chewing gums, wherein a chewing gum is coated with a plaque disrupting emulsion containing an ingestible surfactant and a polydimethyl siloxane emulsified therein, and wherein the emulsion coating can further contain a therapeutic substance such as the gingivitis control substance stannous fluoride.

Abstract: This invention relates to the substance Trehalostatin which is a white powder soluble in water but hardly or only slightly soluble in hexane, benzene, ethers and petroleum ether, shows no absorption maxima at 220 nm or above in its ultraviolet visible light absorption spectrum, is positive in Rydon-Smith reaction and negative in nynhydrin reaction, 3,6-dinitrophthalic acid reaction and Elson-Morgan reaction, and has an RF value of 0.37 in Merck Kieselgal 50 F.sub.254 thin-layer chromatography using 3:1:2 mixture on n-butanol, acetic acid and water as a developing solvent, Rt of 11.0 minutes in YMC PA03 (0.7 .times.27 cm) high performance liquid chromatography using 65% v/v acetonitrile (in H.sub.2 O) as a solvent at a flow rate of 1.0 ml/min, a molecular weight of 366, [alpha].sub.D of +115.degree., and specific NMR spectrum.Also disclosed is a process for preparing trehalostatin and a specific strain of Amycolatopsis trehalostatica which has FERM accession number BP-2784.

Abstract: Disclosed is a syringe assembly which greatly reduces the chances of an operator coming in contact with an infectious needle. The syringe assembly is initially provided with its needle retracted within its barrel, in a sterile and safe environment. When used, the needle is engaged by the plunger, and locked in place at the forward end of the syringe barrel. Before disposal, the needle is withdrawn back into the barrel, and the plunger is broken off. Thus, the disposed of syringe is incapable of being reused, and there is little or no danger of accidental punctures, because the needle is retained within the syringe barrel.

Abstract: An electroless catalytic gold plating solution is disclosed comprising a water soluble organic thiol gold (I) complex, an alkali metal cyanide, an alkali metal hydroxide, a borohydride reducing agent, and may also contain a stabilizing agent. The electroless gold plating solution will deposit gold on a gold surface several times faster than the conventional electroless gold baths based on potassium aurous cyanide. The use of an organic thiol gold (I) complex eliminates the buildup of inhibitory cyanide ions as a result of replenishment.

Abstract: The improvements in shielded safety syringes described herein provide a safe and simple mechanism to reduce and preferably eliminate accidental needle-stick injuries. The improvements described herein further provide a safe and simple means to prevent unauthorized reuse of the syringe. The improved syringe of the present invention locks the needle assembly in the shield member after use, preventing reuse and accidental needle-stick injuries.

Abstract: The present invention relates to a method for sizing of paper by using a particular vinylamine polymer as a size-fixing aid. By the use of the vinylamine polymer as a size-fixing aid, it has become possible to obtain a paper having superior sizing properties by papermaking at a pH around neutrality using a hitherto known acidic sizing agents without using a neutral sizing agent. The method of the present invention further has effects that operating efficiency of papermaking is greatly improved since contaminations of a papermaking machine due to a neutral agent can be avoided, and therefore, the prices of paper can be greatly lowered. The present method has further advantages when it is applied under acidic papermaking condition of a pH of less than 5.5. In such a condition, the addition amount of alum can be decreased and the life of a papermaking machine can be prolonged. In spite of a small amount of alum added, a considerably good sizing effect can be obtained by the present method.

Abstract: N,N-disubstituted-guanidines, e.g., of the formula ##STR1## wherein R and R' are substituted or unsubstituted hydrocarbon groups. Methods are provided for the treatment of psychosis and hypertension by administering an effective amount of an N,N'-disubstituted guanidine which, preferably, has a high affinity for the sigma receptor.

Abstract: This invention relates to additives for methanesulfonic acid based tin and tin alloy plating formulations. Specifically, the invention involves the use of gallic acid in the multiple roles of antioxidant, grain refiner, selective precipitant, and selective chelator in methanesulfonic acid based tin or tin alloy plating formulations.

Abstract: This invention is directed to didemnin derivatives, including N-acyl congeners of didemnin A (DA); several DDB-type analogues of DA in which either pyruvic acid has been replaced (with phenylpyruvic acid or alphaketobutyric acid) or proline at position 8 has been replaced [with L-azetidine-2-carboxylic acid (AZT), L-pipecolic acid (Pip), 1-amino-1-carboxylic cyclopentane (acc.sup.5), D-Pro or sarcosine (sar); and other cyclic depsipeptides related to the didemnins, which were isolated from a relatively polar extract of the tunicate T. solidum; namely the didemnins--X [(R)-3-hydroxy-decanoyl-(Gln).sub.3 -Lac-Pro didemnin A]; Y [(R)-3-hydroxy-decanoyl-(Gln).sub.4 -Lac-Pro didemnin A]; M (pGlu-Gln-Lac-Pro-didemnin A); N ([Tyr.sup.5 ] didemnin B); nordidemnin N ([Tyr.sup.5 ] nordidemnin B); and epididemnin A ([2S,4R-Hip.sup.2 ] didemnin A).

Abstract: Liposomes containing phosphatidylethanolamine, palmitoyl homocysteine or oleic acid or palmitic acid, fuse rapidly when the pH of the medium is reduced below 7. Liposome fusion was measured by (a) mixing of the liposomal lipids as shown by resonance energy transfer, (b) gel filtration and (c) electron microscopy. The presence of phosphatidylethanolamine or acid addition esters thereof in the liposomes greatly enhances fusion; whereas the presence of phosphatidylcholine inhibits fusion. During fusion of liposomes containing phosphatidylethanolamine:palmitoyl homocysteine (8:2), almost all of the encapsulated calcein is released. Inclusion of cholesterol (40%) in the liposomes substantially decreases leakage without impairing fusion. Those pH sensitive liposomes are fused to deliver biologically active molecules such as DNA, into living cells.

Abstract: Baths and methods for the electroplating of tin, tin-lead, tin-antimony, and/or tin-bismuth are described. Specifically, electrodeposition solutions, based on alkanesulfonic acids, soluble metal salts, other additives, and at least one nonionic surfactant terminated with a ketone group, have been developed. The use of ketone (e.g., --OCH.sub.2 COCH.sub.3) terminated polyoxyalkylene surfactants results in electrodeposition solutions with reduced foam, and the tin and tin alloy electrodeposits from such plating baths are of superior quality.

Abstract: Disclosed are cyanide free electroplating solutions for gold or alloys thereof; said solutions comprising gold in the form of a soluble sulfite complex, an added source of sulfite and/or bisulfite ion and a supporting electrolyte; and said solutions further comprising both an organic polyamine or mixture of polyamines of molecular weight from about 60 to 50,000, and an aromatic organic nitro compound; wherein the pH of said solutions is below about 6.5.

Abstract: An apparatus is disclosed for projecting a stiffly flexible conduit or cable through a bore of a tube to be cleaned, surveyed or otherwise processed, said apparatus comprising a drum enabling the conduit or cable to be stored therein in a plurality of wound coils with a distal or free end of the conduit or cable to be projected from the apparatus and into the bore of the tube to be cleaned, surveyed or the like, the drum being mounted for simultaneous axial and rotary motion and drive means being provided to effect the axial and rotary motion of the drum, restraining means being provided to prevent radial expansion of the wound coils on the drum.

Abstract: Tri- and tetra-substituted guanidines which exhibit a high binding affinity to phencyclidine (PCP) receptors and, more preferably, low affinity to the brain sigma receptors. These guanidine derivatives act as non-competitive inhibitors of glutamate induced responses of the NMDA receptor by acting as blockers for the ion channel of the NMDA receptor-ion channel complex. These compounds thus exert neuroprotective activity and are useful in the therapeutic treatment of neuronal loss in hypoxia, hypoglycemia, brain or spinal cord ischemia, and brain or spinal chord trauma as well as being useful for the treatment of epilepsy, Alzheimer's disease, Amyotrophic Lateral Sclerosis, Parkinson's disease, Huntington's disease, Down's Syndrome, Korsakoff's disease and other neurodegenerative disorders.

Abstract: The present invention relates to pharmaceutical compositions comprising matter extracted from the well-known and readily available tropical marine invertebrate, Ecteinascidia turbinata, and designated herein as ecteinascidins, and to the use of such compositions as antibacterial, anti-viral, and/or antitumor agents in mammals.

Abstract: Disclosed are antihypertensive pharmaceutical compositions and compounds which include the thiocarbamoylacetonitrile having the formula: ##STR1## wherein: R.sup.1 is selected from the group consisting of hydrogen, a C.sub.1 to C.sub.6 alkyl, a C.sub.3 to C.sub.6 cycloalkyl or --(CH.sub.2).sub.n --A (where A is selected from the group consisting of a C.sub.6 to C.sub.12 aryl, a 5- or 6-membered heterocyclic group or a fused heterocyclic group constituted by 9 or 10 atoms, each of which may be substituted by at least one substitute group selected from a C.sub.1 to C.sub.6 alkyl and a halogen and n is 0 or an integer of 1 to 6),R.sup.2 represents a C.sub.1 to C.sub.10 alkyl, and Ar represents an aryl, a 5- or 6-membered heterocyclic group or a fused heterocyclic group, each of which may be substituted by at least one substituent group selected from the group consisting of a C.sub.1 to C.sub.6 alkyl, a C.sub.1 to C.sub.6 alkoxy, a C.sub.2 to C.sub.7 alkylcarbonyl, a C.sub.7 to C.sub.

Abstract: Disclosed are monoclonal antibodies having an affinity for endothelin-3 or a precursor thereof; a hybridoma cell which produces the monoclonal antibody; and an immunoassay of endothelin-3 and big endothelin-3, a precursor of endothelin-3, by a sandwich method or a competitive method. The monoclonal antibodies can be used as strong antagonists for endothelin-3 in various endothelin-3-related diseases, and the immunoassays make it possible to determine endothelin-3 and big endothelin-3 with high sensitivity.

Abstract: Slipper type article and method for the application and removal of water sports apparel such as wet suits, dry suits and wet suit booties. The slipper is composed of a hydrophobic material such as ripstop nylon. The slipper aids the entry and withdrawal of a foot through the narrow leg openings of wet suits, dry suits and wet suit booties.

Abstract: Disclosed herein are anxiolytic drugs containing as an active ingredient a piperazine derivative represented by the following general formula (I): ##STR1## wherein m represents an integer from 2 to 4,X represents ##STR2## Ar represents a pyridyl group, a pyrimidinyl group, or a phenyl group which may be substituted with halogen atom, trifluoromethyl group, alkoxy group or alkyl group, andR.sub.1, R.sub.2 and R.sub.3 which may be identical or different represent lower alkoxy groups, or R.sub.3 is a hydrogen atom and R.sub.1 when taken together with R.sub.2 forms ##STR3## (n=1, 2 or 3); and its acid addition salt.The anxiolytic drugs disclosed herein have the high binding capacities to 5-HT.sub.1A receptor which is one of the receptors for 5-hydroxytryptamine (5-HT), thereby exerting anxiolytic effects.